Most therapeutic agents used for treating brain malignancies face hindered transport through the blood–brain barrier (BBB) and poor tissue penetration. To overcome these problems, we developed peptide conjugates of conventional experimental anticancer agents. SynB3 cell-penetrating derivatives were applied that can cross BBB. Tuftsin to target neuropilin-1 system selectivity better tumor Moreov...